|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||79.40 - 81.00|
|52 Week Range||76.52 - 89.72|
|PE Ratio (TTM)||39.09|
|Earnings Date||May 24, 2018|
|Forward Dividend & Yield||1.84 (2.30%)|
|1y Target Est||91.40|
In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise. The company has earned ~48.4% of its total revenue from its plasma franchise YTD (year-to-date) in fiscal 2018. Approximately 91% of the plasma segment’s total revenue in fiscal 2017 was attributable to the sale of disposables.
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%. Haemonetics has earned revenue of nearly $324.4 million from the sale of its products in the plasma franchise YTD (year-to-date) in fiscal 2018, which reflects a YoY rise of ~4.7%. The franchise has reported organic revenue growth of close to 6% YTD in fiscal 2018, and it’s expected to continue witnessing robust growth owing to solid demand for drugs based on human plasma.
As of March 15, 2018, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) ratio of 19.2x. The stock has a current PE ratio of 34.9x. For the calculation of the forward PE multiple of a company, the company’s current stock price is divided by the next 12-month earnings estimates for the company. The multiple is an estimate of the potential growth of the company over the next 12 months.
Positive Data on Exclusive AdaptivCRT(TM) Feature Unveiled at EHRA Scientific Sessions 2018 DUBLIN and BARCELONA, Spain - March 20 , 2018 - Two real-world analyses featuring the Medtronic plc (NYSE: MDT) ...
DUBLIN and BARCELONA, Spain - MARCH 19, 2018 - Medtronic plc (NYSE: MDT) today announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance(TM) Cryoballoon to ...
A firestorm in cardiology resulted when a major NIH-funded clinical trial changed its design and moved the goalposts just before reaching completion.
Medical bills can cost hundreds of thousands of dollars in retirement, so it's important to have steady income coming in. Try these good dividend-paying stocks on for size.
Headquartered in Utica, New York, ConMed (CNMD) currently employs 3,100 people worldwide. In 4Q17, ConMed reported total sales close to $222.6 million, which represents a YoY (year-over-year) rise of ~7.9% on a CC (constant currency) basis and 9% on a reported basis, driven by the robust uptake of its products in the US and in international geographies. For fiscal 2017, ConMed reported total sales close to $796 million, which represents a YoY rise of ~4.3%, both on a CC and reported basis.
Medtronic, (MDT) presenting favorable results from the studies based on the CoreValve TAVR system might boost the top line, with increased uptake of the product.
Cash-rich businesses with sustainable and growing yields don't often go on sale, but we found 10 bargain stocks in the Morningstar US Dividend Growth Index.
DUBLIN - March 13, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Oppenheimer 28 th Annual Healthcare Conference on Tuesday, March ...
`Smart` CGM System Provides Predictive Alerts for Dangerous Sensor Glucose Levels; Exclusive Access to Sugar.IQ Assistant with Watson Offers More Proactive Diabetes Management DUBLIN - March 12, 2018 ...
On February 28, 2018, Medtronic (MDT) announced that it has entered into a partnership with LVHN (Lehigh Valley Health Network), an eight-hospital network. LVHN has a presence in seven counties in Northeastern Pennsylvania.
Medtronic Seeks Up to 20 Runners Who Benefit from Medical Technology Selected Runners Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October 2018 Applications ...
Presented at ACC.18, Five-Year Follow-up from the CoreValve Extreme Risk and NOTION Studies Show Sustained Valve Function and Durability Over Time DUBLIN and ORLANDO - March 10, 2018 - Medtronic plc (NYSE: ...
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3, the latest and most accurate CGM (continuous glucose monitoring) sensor. The expanded indication will enable the sensor to be worn on the upper arm, thus providing more flexibility, higher accuracy, and enhanced performance. It is the only sensor approved for use with Medtronic’s MiniMed 670G, which is the first HCL (hybrid closed loop) insulin delivery system in the world.
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set, the newest addition to its portfolio of MiniMed infusion sets. The device is used for insulin delivery from an insulin pump to a person’s body. In late 2018, Medtronic plans to expand the commercial availability of the device in other geographies around the world.
The outlook for the US medical products and devices industry has been revised upward, to positive from stable, Moody's Investors Service says in a just-published report. Continued product innovation and ...
DUBLIN - March 9, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will answer questions about the company on Wednesday, March 14, 2018, in Miami, Florida. Karen ...
As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x. The forward estimate is lower than the current PE ratio, which reflects the analysts’ expectations for higher company earnings over the next 12 months. To calculate the forward PE for a company, the current stock price of the company is divided by its earnings estimates for the next 12 months.